Live Breaking News & Updates on இணைவு ஆன்டிபாடிகள்
Stay updated with breaking news from இணைவு ஆன்டிபாடிகள். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Diaceutics PLC (AIM:DXRX) | RNS | Diaceutics PLC - New Vice President of Finance appointment proactiveinvestors.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from proactiveinvestors.co.uk Daily Mail and Mail on Sunday newspapers.
Fusion is a Belfast based contract research organisation ( CRO ) providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications.
The Company s ordinary shares were admitted to trading on AIM on 18 December 2017. Fusion provides a broad range of services in antibody generation, development, production, characterisation and optimisation. These services include antigen expression, antibody production, purification and sequencing, antibody humanisation using Fusion s proprietary CDRx TM platform and the production of antibody generating stable cell lines to provide material for use in clinical trials. Since 2012, the Company has successfully sequenced and expressed over 250 antibodies and successfully completed over 200 humanisation projects and has an international, blue-chip client base, which has included eight of the top 10 global pharmaceutical companies by r ....
Introduction This interim management statement covers the first quarter of the 2020/21 financial year, 1 October 2020 to 31 December 2020. Investment performance measures contained in this report are calculated on a pence per share basis and include realised and unrealised gains and losses. Investment report The quarter started with three areas of significant concern: a contested US election result; a no deal departure from the European Union; and a winter resurgence of CV19 pandemic. The eventual resolution to the two political risks will in time get greater attention, but for now we remain focussed on understanding and navigating the short-term consequences of the pandemic. ....
Fusion Antibodies, a Belfast-based pharmaceutical contract research company, has appointed Dr Richard Jones as its chief executive. He replaces Dr Paul Kerr who is standing down from the board with immediate effect in order to pursue other opportunities. Dr Kerr will become a consultant to the company. Fusion Antibodies said Dr Jones has 25 years’ experience in the pharmaceutical industry both in big pharma and biotech companies as well as running a contract development and manufacturing organisation (CDMO). He joins Fusion from BrYet, a biotech company focused on the discovery and development of transtherapeutics nanotechnology used for the treatment of metastatic liver and lung cancers. ....
16 February 2021 | 09:56am StockMarketWire.com - contract research organization Fusion Antibodies said it had appointed Dr Richard Jones as chief executive officer, replacing Dr Paul Kerr. Kerr would become a consultant to the company so that he can continue to support the Company going forward, the company said. Concurrent with his stepping down from the board, Kerr was exercising 125,000 options over ordinary shares of 4 pence each in the company at an exercise price of 4 pence per option, it added. At 9:56am: [LON:FAB] Fusion Antibodies Plc Ord 4p share price was 0p at 132.5p Story provided by StockMarketWire.com Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account. ....